Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

Biomarkers for a more precise patient care are needed in metastatic prostate cancer (mPC). We have reported a Phase II trial (TOPARP-A) of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib in mPC, demonstrating antitumor activity associating with homologous recombination DNA repair defects....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Discov
Main Authors: Goodall, Jane, Mateo, Joaquin, Yuan, Wei, Mossop, Helen, Porta, Nuria, Miranda, Susana, Perez-Lopez, Raquel, Dolling, David, Robinson, Dan, Sandhu, Shahneen, Fowler, Gemma, Ebbs, Berni, Flohr, Penny, Seed, George, Rodrigues, Daniel Nava, Boysen, Gunther, Bertan, Claudia, Atkin, Mark, Clarke, Matthew, Crespo, Mateus, Figueiredo, Ines, Riisnaes, Ruth, Sumanasuriya, Semini, Rescigno, Pasquale, Zafeiriou, Zafeiris, Sharp, Adam, Tunariu, Nina, Bianchini, Diletta, Gillman, Alexa, Lord, Christopher J, Hall, Emma, Chinnaiyan, Arul M., Carreira, Suzanne, de Bono, Johann S.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143169/
https://ncbi.nlm.nih.gov/pubmed/28450425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0261
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki